Table 1 The characteristics of the patients with ankylosing spondylitis (AS), ulcerative colitis (UC), and healthy controls (HC)
|  | AS (n = 150) | UC (n = 18) | HC (n = 17) |
|---|---|---|---|
Women/men, n (%) | 68 (45.3)/82 (54.7) | 8 (44.4)/10 (55.6) | 6 (35.5)/11 (64.7) |
Age, years | 55.5 (46–67) | 30.5 (27–39) | 22 (21–31) |
AS symptom duration, years | 28.5 (18–39) |  |  |
HLAB27 positive, n (%) | 127 (84.7) | Â | Â |
BAS-G, score | 2.8 (1.5–5.9) |  |  |
ASDAS-CRP, score | 2.1 (1.3–1.7) |  |  |
BASDAI, score | 3.2 (1.8–5.2) |  |  |
BASFI, score | 2.3 (1.1–4.1) |  |  |
BASMI, score | 3.4 (2.4–4.6) |  |  |
ESR, mm/h | 8 (4–14) |  |  |
CRP, mg/L | 3 (1–6) | 5 (3.5–16.5) | 1 (1–1) |
Fecal calprotectin, mg/kg | 80 (0–190) | 606 (29–10,320) | All < 15 |
Patients on NSAIDs, n (%) | 115 (76.7) | 0 | 0 |
 - Daily use of NSAIDs | 61 (40.7) |  |  |
 - On-demand use of NSAIDs | 54 (36.0) |  |  |
On TNFi all, n (%) | 35 (23.3) | 0 | N.A. |
 - TNFi in monotherapy | 16 (10.7) |  |  |
 - TNFi + methotrexate | 19 (12.7) |  |  |
On DMARD monotherapy | 16 (10.7) | 0 | N.A. |
 - Methotrexate | 9 (6.0) |  |  |
 - Sulfasalazine | 7 (4.7) |  |  |